Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabKimio Yonesaka, Pasi A. Jänne, Jeffrey A. Engelman et al.|Science Translational Medicine|2011Cited by 670
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> MutationsSatoshi Morita, Toshihiro Nukiwa, Isamu Okamoto et al.|Clinical Cancer Research|2009Cited by 189
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung CancerJunko Tanizaki, Kazuhiko Nakagawa, Isamu Okamoto et al.|Clinical Cancer Research|2012Cited by 156
The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancerHidetoshi Hayashi, Kazuto Nishio, Tokuzo Arao et al.|Oncogene|2013Cited by 143
Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non–Small Cell Lung CancerDaisuke Shibahara, Isamu Okamoto|Journal of Thoracic Oncology|2018Cited by 38